AG
CTKB icon

Algert Global’s Cytek Biosciences CTKB Stock Holding History

Algert Global’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$186K Buy
+42,560
New +$201K ﹤0.01% 1090
2025
Q3 		– Sell
-372,238
Closed -$1.27M – 1169
2025
Q2 		$1.27M Sell
372,238
-39,187
-10% -$131K 0.03% 756
2025
Q1 		$1.65M Buy
411,425
+60,510
+17% +$314K 0.04% 655
2024
Q4 		$2.28M Buy
350,915
+21,540
+7% +$128K 0.05% 562
2024
Q3 		$1.82M Buy
329,375
+34,100
+12% +$193K 0.05% 579
2024
Q2 		$1.65M Buy
295,275
+168,665
+133% +$1.01M 0.05% 525
2024
Q1 		$850K Buy
126,610
+14,350
+13% +$113K 0.03% 654
2023
Q4 		$1.02M Buy
+112,260
New +$707K 0.04% 613
2023
Q2 		– Sell
-25,679
Closed -$236K – 1116
2023
Q1 		$236K Sell
25,679
-47,634
-65% -$512K 0.01% 994
2022
Q4 		$749K Buy
73,313
+27,258
+59% +$366K 0.04% 681
2022
Q3 		$678K Buy
46,055
+24,785
+117% +$322K 0.04% 706
2022
Q2 		$228K Buy
+21,270
New +$212K 0.02% 989

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Algert Global's CTKB Position: Q1 2026 in Review

Algert Global opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 42,560 shares worth $186K. The stake represents ﹤0.01% of the portfolio and ranks #1090 among its holdings. This is a return to the name: Algert Global previously reported a position in CTKB as recently as Q2 2025.

Algert Global first reported a position in CTKB in Q2 2022 and has held it in 12 quarters since. The position peaked at $2.28M in Q4 2024. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Algert Global held 42,560 shares of Cytek Biosciences worth $186K as of Q1 2026.
  • Cytek Biosciences was a new Algert Global position in Q1 2026.
  • Cytek Biosciences made up ﹤0.01% of Algert Global's portfolio in Q1 2026, its #1090 holding.
  • Algert Global first reported a position in Cytek Biosciences in Q2 2022 and has held it in 12 quarters since.
  • Algert Global's Cytek Biosciences position peaked at $2.28M in Q4 2024.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.